Explore the Site

  • Latest News
  • AusBiotech
  • Events
  • About
  • Contact
  • Subscribe
  • Search

Follow Us

  • LinkedIn
  • Twitter
  • Instagram
BiotechDispatch Menu
November 20, 2026
  • Subscribe
  • Login
  • Latest News
  • AusBiotech
  • Events
  • About
  • Contact
  • Subscribe
  • Search

Sign In

  • Forgot password?
  • Latest News

    Immutep goes back to smaller batch efti after review finds glycan differences in trial candidate

    November 19, 2026
  • Latest News

    Genetic Signatures walks away from Microba merger after funding shortfall

    November 19, 2026
  • Latest News

    Independent review backs a fresh look at Paradigm's iPPS outside the US

    November 19, 2026
  • Latest News Syntara looks for a partner after promising amsulostat data November 19, 2026
    At its annual general meeting on Thursday, Syntara said that amsulostat, its lead blood cancer drug, is ready for a larger trial. Chief executive Gary Phillips cited a run of major pharmaceutical deals in myelofibrosis as evidence of what could follow.
  • Latest News Actinogen's Xanamem misses primary endpoint in pivotal Alzheimer's trial as company turns to older patients November 19, 2026
    Actinogen Medical's pivotal Alzheimer's disease trial of emestedastat, which the company is developing as Xanamem, has not demonstrated a statistically significant benefit on its primary endpoint.
  • AusBiotech AusBiotech opens call for sessions for Brisbane's 2027 'Biggest Week in Biotech' November 17, 2026
    AusBiotech has opened its call for session proposals for Australia's Biggest Week in Biotech 2027, which will be held in Brisbane from 23 to 27 August next year. Proposals close on Friday 19 February 2027.
  • Latest News Neurizon moves first HEALEY ALS participant into NUZ-001 extension ahead of 2027 readout November 17, 2026
    Neurizon Therapeutics says the first participant in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial has finished the 36-week placebo-controlled phase and moved into the Active Treatment Extension. This is the next step for the regimen after enrolment of 250 participants was completed in July 2026.
  • Latest News Racura bridges new bisantrene formulation to earlier AML trial results November 17, 2026
    Racura Oncology says a new formulation of its lead drug bisantrene delivers the same drug exposure as the earlier version used in two acute myeloid leukaemia trials. The company says this lets it draw on that clinical record as it moves the new product into a Phase 2b/3 study.
  • Latest News Radiopharm brain metastases imaging agent closely matches MRI in interim Phase 2b data November 17, 2026
    Radiopharm Theranostics has reported interim results from a Phase 2b study of its imaging agent RAD101 in patients with suspected recurrent brain metastases after radiotherapy. The PET scans agreed with contrast-enhanced MRI in 93.5 per cent of patients.
  • BCAL widens breast cancer research beyond lipids as its science goes through peer review November 17, 2026
    BCAL Diagnostics has received ethics approval to take its breast cancer research beyond lipids. The company is also building the scientific record behind its blood test, with a paper published in a Nature Portfolio journal and a second now in revision.
  • Latest News Cartherics takes ovarian cancer cell therapy to London as first human trial nears November 11, 2026
    Melbourne biotechnology company Cartherics will use London Life Sciences Week to seek international partners, collaborators, and investors as its lead ovarian cancer therapy moves toward its first human trial.
  • Latest News Brandon Capital opens its Melbourne office doors to biotech tenants November 11, 2026
    Brandon Capital is inviting biotechnology, healthcare and life sciences businesses to take up office space alongside it at 31 Queen Street in the Melbourne CBD, where the venture investor has its Melbourne base on Level 9.
  • Celairis signs first major licensing deal with Ocugen's gene therapy for retinitis pigmentosa November 12, 2026
    Celairis Therapeutics has secured exclusive rights to commercialise Ocugen's investigational gene therapy for retinitis pigmentosa in Australia, New Zealand and the member states of the Association of Southeast Asian Nations.
  • Latest News Immutep's efti combination shows early survival signal in soft tissue sarcoma November 11, 2026
    Immutep has released the first survival data from EFTISARC NEO, a Phase II trial of its immunotherapy eftilagimod alfa in patients with soft tissue sarcoma that can be surgically removed. The results will be presented at the Connective Tissue Oncology Society annual meeting in Seoul later this month.
  • Latest News Syntara pauses scar study recruitment after skin irritation reports November 11, 2026
    Syntara has paused recruitment in its Phase 1b study of SNT-9465 after some participants reported mild to moderate skin irritation from the topical scar treatment.
  • Miro Sciences clears TGA manufacturing inspection ahead of Crohn's trial November 12, 2026
    The Therapeutic Goods Administration has completed its inspection of Q-Gen Cell Therapeutics, the Brisbane contract manufacturer that will make Miro Sciences' StemSmart stem cell product for a planned Phase 2 trial in refractory Crohn's disease.
  • Latest News NuNerve launches 75-patient Phase 2 MND trial of NUN-004 November 10, 2026
    NuNerve is taking its lead motor neurone disease therapy into a national Phase 2 trial after early signs of disease stabilisation and functional improvement in its first human study.
  • Latest News CLINUVEL bets its cash reserves on long acting injectables and a possible US listing November 9, 2026
    CLINUVEL managing director Philippe Wolgen has rejected calls from some shareholders for a share buyback. At the company's annual general meeting in Melbourne, he said the board would keep investing cash in research and a planned business transformation.
  • Latest News AVITA Medical raises guidance as Medicare locks in RECELL payment codes November 9, 2026
    AVITA Medical has raised its full-year revenue guidance and removed the going concern qualification from its accounts after a third quarter in which revenue grew 53 per cent on the same period last year.
  • Latest News Nexsen targets 2027 FDA filing for bedside kidney injury test November 9, 2026
    Nexsen says it aims to file its RenalSure bedside test for acute kidney injury with the US Food and Drug Administration in mid-2027. It has also started a feasibility study with Austrian company GENSPEED Biotech to evaluate a second, complementary test for the condition.

Most Read

  • Actinogen's Xanamem misses primary endpoint in pivotal Alzheimer's trial as company turns to older patients

    November 19, 2026 - Latest News
  • Genetic Signatures walks away from Microba merger after funding shortfall

    November 19, 2026 - Latest News
  • Independent review backs a fresh look at Paradigm's iPPS outside the US

    November 19, 2026 - Latest News
  • Syntara looks for a partner after promising amsulostat data

    November 19, 2026 - Latest News
  • Immutep goes back to smaller batch efti after review finds glycan differences in trial candidate

    November 19, 2026 - Latest News

Follow Us

  • LinkedIn
  • Twitter
  • Instagram

New Stories

  • Actinogen's Xanamem misses primary endpoint in pivotal Alzheimer's trial as company turns to older patients

    November 19, 2026 - - Latest News
  • Independent review backs a fresh look at Paradigm's iPPS outside the US

    November 19, 2026 - - Latest News
  • Syntara looks for a partner after promising amsulostat data

    November 19, 2026 - - Latest News
  • Genetic Signatures walks away from Microba merger after funding shortfall

    November 19, 2026 - - Latest News
  • Immutep goes back to smaller batch efti after review finds glycan differences in trial candidate

    November 19, 2026 - - Latest News
  • BCAL widens breast cancer research beyond lipids as its science goes through peer review

    November 17, 2026 -
  • AusBiotech opens call for sessions for Brisbane's 2027 'Biggest Week in Biotech'

    November 17, 2026 - - AusBiotech
  • About Us
  • Contact Us
  • Privacy Policy
  • Subscribe
  • Powered by Newsroom

©2026 DailyDispatch Pty Ltd. All Rights Reserved.